Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 12,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: combined therapy treatment Clear all

Conditions: Non-Small Cell Lung Cancer
Interventions: Sorafenib + Docetaxel/Carboplatin; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: endocrine-modulating drug therapy, mitoxantrone hydrochloride, prednisone, prinomastat; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Tumors
Interventions: Sunitinib malate, Rapamycin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions: fluorouracil, pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment; Drug · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Glioma, IDH-mutant Gliomas
Interventions: Vorasidenib, Lomustine; Drug
Lead sponsor: Megan Mantica; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: Enzalutamide, Metformin Hydrochloride; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Solid Tumors
Interventions: Temsirolimus, Pazopanib; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Pancreatic Cancer
Interventions: Rintatolimod; Drug
Lead sponsor: AIM ImmunoTech Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 3
States / cities: Omaha, Nebraska • Canton, Ohio • Seattle, Washington

Conditions: Pancreatic Cancer
Interventions: PBP1510 (400mg/16mL), Gemcitabine (1000 mg/m^2); Drug
Lead sponsor: Prestige Biopharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Post Menopausal Osteoporosis
Interventions: Placebo, Vitamin D and calcium supplementation, ibandronate [Bonviva/Boniva]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 65 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Beverly Hills, California • La Jolla, California • Augusta, Georgia + 4 more

Conditions: Skin Laxity
Interventions: Ulthera® System, Sculptra®, Sculptra® treatment followed by Ultherapy™ treatment; Device · Drug · Other
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 35 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ovarian Neoplasms
Interventions: Telcyta, Liposomal Doxorubicin; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 63
States / cities: Casa Grande, Arizona • Little Rock, Arkansas • Antioch, California + 49 more

Conditions: Breast Cancer
Interventions: Fulvestrant, Alpelisib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 34
States / cities: Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more

Conditions: Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions: Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 112
States / cities: Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more

Conditions: Locally Advanced or Metastatic Solid Tumors
Interventions: LUNA18, Cetuximab; Drug
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 13
States / cities: Davis, California • Boston, Massachusetts • Detroit, Michigan + 9 more

Conditions: Opsoclonus-myoclonus Syndrome
Interventions: Not listed
Lead sponsor: National Pediatric Neuroinflammation Organization, Inc.; Other
Eligibility: 1 Year to 18 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Non Small Cell Lung Cancer
Interventions: 2.5 Gy/fraction, Carboplatin, Paclitaxel; Radiation · Drug
Lead sponsor: Stephanie Smiddy; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Healthy Participants
Interventions: Metformin, Sevabertinib (BAY 2927088); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Small Cell Lung Cancer
Interventions: Alisertib, Placebo, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • New Haven, Connecticut + 18 more

Conditions: Ovarian Cancer, Chemotherapeutic Toxicity
Interventions: Fasting Mimicking Diet (Xentigen by L'Nutra), Carboplatin, Paclitaxel, Standard diet; Dietary Supplement · Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 27
States / cities: Birmingham, Alabama • Harbor City, California • Los Angeles, California + 15 more

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine and Cedazuridine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aortic Stenosis
Interventions: Prehabilitation, Usual Care; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer

Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy

Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer

VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)

Ultherapy™ Treatment Following Sculptra® Treatment

Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome

Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer

Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer

A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Prehabilitation to Improve Functional and Clinical Outcomes in Patients With Aortic Stenosis